Evidence map›Paper›PMID 39725965›Full record

ArticleParticle and fibre toxicology2024

Hazard assessment of nanomaterials: how to meet the requirements for (next generation) risk assessment.

Eleonora Marta Longhin, Ivan Rios-Mondragon, Espen Mariussen, Congying Zheng, Martí Busquets, Agnieszka Gajewicz-Skretna, Ole-Bendik Hofshagen, Neus Gómez Bastus, Victor Franco Puntes, Mihaela Roxana Cimpan and 3 more

Abstract read
In one paragraph

Article in Particle and fibre toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eleonora Marta LonghinHealth Effects Laboratory, Department of Environmental Chemistry and Health Effects, NILU, 2007, Kjeller, Norway. eml@nilu.no.
Ivan Rios-MondragonDepartment of Clinical Dentistry, Faculty of Medicine, University of Bergen, Årstadveien 19, 5009, Bergen, Norway.
Espen MariussenHealth Effects Laboratory, Department of Environmental Chemistry and Health Effects, NILU, 2007, Kjeller, Norway.
Congying ZhengNorgenotech AS, Ullernchausseén 64, 0379, Oslo, Norway.
Martí BusquetsApplied Nanoparticles SL, Alaba 88, 08018, Barcelona, Spain.
Agnieszka Gajewicz-SkretnaLaboratory of Environmental Chemoinformatics, Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland.
Ole-Bendik HofshagenDepartment of Clinical Dentistry, Faculty of Medicine, University of Bergen, Årstadveien 19, 5009, Bergen, Norway.
Neus Gómez BastusInstitut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain.
Victor Franco PuntesInstitut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain.
Mihaela Roxana CimpanDepartment of Clinical Dentistry, Faculty of Medicine, University of Bergen, Årstadveien 19, 5009, Bergen, Norway.
Sergey ShaposhnikovNorgenotech AS, Ullernchausseén 64, 0379, Oslo, Norway.
Maria DusinskaHealth Effects Laboratory, Department of Environmental Chemistry and Health Effects, NILU, 2007, Kjeller, Norway.
Elise Rundén-PranHealth Effects Laboratory, Department of Environmental Chemistry and Health Effects, NILU, 2007, Kjeller, Norway. erp@nilu.no.

Funding

H2020 Industrial Leadership SABYDOMA (grant no. 862296)H2020 Spreading Excellence and Widening Participation TWINALT (grant no. 952404-H2020-WIDESPREAD-2020-5)Norges Forskningsråd NanoBioReal (grant no. 288768)
6 · The paper itself

Abstract

backgroundHazard and risk assessment of nanomaterials (NMs) face challenges due to, among others, the numerous existing nanoforms, discordant data and conflicting results found in the literature, and specific challenges in the application of strategies such as grouping and read-across, emphasizing the need for New Approach Methodologies (NAMs) to support Next Generation Risk Assessment (NGRA). Here these challenges are addressed in a study that couples physico-chemical characterization with in vitro investigations and in silico similarity analyses for nine nanoforms, having different chemical composition, sizes, aggregation states and shapes. For cytotoxicity assessment, three methods (Alamar Blue, Colony Forming Efficiency, and Electric Cell-Substrate Impedance Sensing) are applied in a cross-validation approach to support NAMs implementation into NGRA.

resultsThe results highlight the role of physico-chemical properties in eliciting biological responses. Uptake studies reveal distinct cellular morphological changes. The cytotoxicity assessment shows varying responses among NMs, consistent among the three methods used, while only one nanoform gave a positive response in the genotoxicity assessment performed by comet assay.

conclusionsThe study highlights the potential of in silico models to effectively identify biologically active nanoforms based on their physico-chemical properties, reinforcing previous knowledge on the relevance of certain properties, such as aspect ratio. The potential of implementing in vitro methods into NGRA is underlined, cross-validating three cytotoxicity assessment methods, and showcasing their strength in terms of sensitivity and suitability for the testing of NMs.

Indexed as

NanostructuresAnimalsCell SurvivalComet AssayComputer SimulationDNA DamageHumansParticle SizeRisk AssessmentToxicity TestsHazard assessmentNanomaterialsNew approach methodologiesNext generation risk assessmentSafe and sustainable by design

Identifiers

PMID39725965
PMCPMC11674189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.